Genmab — Februar 2013
-
-
Stadige fremskridt med Genmab som deltager http://www.biomedexperts.com/Abstract.bme/23183273/A_quantitative_flow_cytometric_assay_for_determining_binding_characteristics_of_chimeric_humanized_and_human_antibodies
-
Det omhandlede link er noget der efterspørges af sundhedsmyndigheder for at at optimere dosering og virkning billigst muligt - "Our data indicate that the calibrator assay has all properties required for a pharmacodynamic tool to quantify target occupancy of chimeric, humanized and human therapeutic antibodies during therapy, as well as to collect valuable information on both antibody and antigen kinetics"
-
-
Jeg har mange GSK i pension.
-
Men det her viser igen igen at Arzerra tallene er fuldstændig irrelevante for aktiekursen som jeg har sagt længe.
-
Det er nye labels der er det afgørende (og nye markeder)
-
Lav omsætning tilbage i Genmab. Lidt sørgeligt
-
Old normal is back
-
-
Genmab’s daratumumab has the potential to be a game changer. Activity of the anti-CD38 antibody in myeloma represents a new and complementary mechanism of action, meeting a major unmet medical need. Heavily pre-treated multiple myeloma patients extraordinarily achieved a partial response after short single-agent exposure.
-
Although early stage, the data is sufficiently impressive for J&J and Genmab to communicate an ambitious clinical trial programme this year across a variety of haematological cancers, targeting a market opportunity of c $9bn.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind